FIELD: pharmacology.
SUBSTANCE: invention relates to application of lithium ascorbate in a dose of at least 5 mg/kg as an agent for prevention and treatment of chronic alcoholic intoxication. Application, among all, is characterized by protection of brain neurons and reduction of demyelinating complications.
EFFECT: expanded arsenal of means for the specified purpose.
4 cl, 1 ex, 3 tbl, 10 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| LOW MOLECULAR WEIGHT MIMETIC OF BRAIN NEUROTROPHIC FACTOR WITH ANALGESIC, ANXIOLYTIC AND ANTIADDICTIVE EFFECTS | 2020 |
|
RU2759023C2 |
| AGENT FOR MANAGING ALCOHOL ABSTINENCE SYNDROME | 2012 |
|
RU2521226C2 |
| CARDIOTROPIC AGENT WITH ANXIOLYTIC AND ANALGESIC PROPERTIES | 2020 |
|
RU2773018C2 |
| 7-O-[6-O-(4-ACETYL-α-L-RHAMNOPYRANOSYL)-β-D-GLUCOPYRANOSIDO]-5-HYDROXY-6-METHOXY-2-(4-METHOXY-PHENYL)-4H-CHROMONE-4-ON, HAVING ANTI-ALCOHOL ACTION ON HIGHER NERVOUS ACTIVITY | 2014 |
|
RU2605377C2 |
| AGENT FOR TREATMENT OF BRAIN ISCHEMIC INJURY | 2004 |
|
RU2288714C2 |
| DERIVATIVE OF PYRROLIDINE ACETAMIDE OR ITS COMBINATION FOR TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | 2000 |
|
RU2261093C2 |
| ANXIOLYTIC AND CEREBROPROTECTIVE AGENT REDUCING INCLINATION TO ALCOHOL | 2008 |
|
RU2393855C1 |
| POROUS SORBENT WITH NORMOTHYMIC PROPERTIES BASED ON ALUMINIUM OXIDE | 2016 |
|
RU2620118C1 |
| DRUG FOR GASTROINTESTINAL TRACT AND HEPATOBILIARY SYSTEM DISEASES TREATMENT AND PREVENTING RECRUDESCENCES | 2017 |
|
RU2651711C1 |
| METHOD FOR PREVENTING AND CORRECTING METABOLIC AND FUNCTIONAL DISORDERS OF THE CENTRAL NERVOUS SYSTEM UNDER STRESS CONDITIONS | 2019 |
|
RU2717107C1 |
